CN103492412A - 分枝型peg修饰的glp-1类似物及其可药用盐 - Google Patents

分枝型peg修饰的glp-1类似物及其可药用盐 Download PDF

Info

Publication number
CN103492412A
CN103492412A CN201280018158.0A CN201280018158A CN103492412A CN 103492412 A CN103492412 A CN 103492412A CN 201280018158 A CN201280018158 A CN 201280018158A CN 103492412 A CN103492412 A CN 103492412A
Authority
CN
China
Prior art keywords
glp
pex
lys
analogs
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201280018158.0A
Other languages
English (en)
Other versions
CN103492412B (zh
Inventor
王瑞军
赵军军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Best Pharmaceutical Co ltd
Lianyungang Hongchuang Pharmaceutical Co ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Original Assignee
Jiangsu Hansen Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansen Pharmaceutical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansen Pharmaceutical Co Ltd
Priority to CN201280018158.0A priority Critical patent/CN103492412B/zh
Publication of CN103492412A publication Critical patent/CN103492412A/zh
Application granted granted Critical
Publication of CN103492412B publication Critical patent/CN103492412B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

提供了分枝型PEG修饰的GLP-1类似物及其可药用盐、其制备方法、含有治疗有效量的该类似物的药物组合物，及其制备治疗和/或预防Ⅱ型糖尿病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201280018158.0A 2011-05-19 2012-04-26 分枝型peg修饰的glp-1类似物及其可药用盐 Active CN103492412B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280018158.0A CN103492412B (zh) 2011-05-19 2012-04-26 分枝型peg修饰的glp-1类似物及其可药用盐

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2011101373301A CN102786590A (zh) 2011-05-19 2011-05-19 分枝型peg修饰的glp-1类似物及其可药用盐
CN201110137330.1 2011-05-19
CN201280018158.0A CN103492412B (zh) 2011-05-19 2012-04-26 分枝型peg修饰的glp-1类似物及其可药用盐
PCT/CN2012/074706 WO2012155780A1 (zh) 2011-05-19 2012-04-26 分枝型peg修饰的glp-1类似物及其可药用盐

Publications (2)

Publication Number Publication Date
CN103492412A true CN103492412A (zh) 2014-01-01
CN103492412B CN103492412B (zh) 2015-12-23

Family

ID=47152194

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011101373301A Pending CN102786590A (zh) 2011-05-19 2011-05-19 分枝型peg修饰的glp-1类似物及其可药用盐
CN201280018158.0A Active CN103492412B (zh) 2011-05-19 2012-04-26 分枝型peg修饰的glp-1类似物及其可药用盐

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2011101373301A Pending CN102786590A (zh) 2011-05-19 2011-05-19 分枝型peg修饰的glp-1类似物及其可药用盐

Country Status (2)

Country Link
CN (2) CN102786590A (zh)
WO (1) WO2012155780A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345226B (es) 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
WO2012007880A2 (en) * 2010-07-16 2012-01-19 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
DK2976325T3 (en) 2013-03-21 2017-06-06 Sanofi Aventis Deutschland SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID
CN103724424B (zh) * 2013-12-27 2015-05-27 浙江省农业科学院 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用
US20160151511A1 (en) 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
BR112017023145A2 (pt) 2015-06-04 2018-07-10 Antriabio Inc Método para produzir um conjugado de proteína- peg
AU2016379403B2 (en) * 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
CN109929025A (zh) * 2017-12-18 2019-06-25 江苏豪森药业集团有限公司 一种基于反应动力学的聚乙二醇洛塞那肽的制备方法
KR20230083294A (ko) * 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074600A1 (fr) * 2005-01-14 2006-07-20 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Exendines modifiees et utilisations correspondantes
CN1832959A (zh) * 2003-03-19 2006-09-13 伊莱利利公司 聚乙二醇连接的glp－1化合物
CN101868476A (zh) * 2007-09-05 2010-10-20 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100344323C (zh) * 2004-09-30 2007-10-24 华东师范大学 一种人胰高血糖素样肽－1的复合物及其制备方法
US8183340B2 (en) * 2005-05-13 2012-05-22 Eli Lilly And Company GLP-1 pegylated compounds
WO2007075534A2 (en) * 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
EP2636680A3 (en) * 2006-05-26 2013-12-11 Amylin Pharmaceuticals, LLC Composition and methods for treatment of congestive heart failure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832959A (zh) * 2003-03-19 2006-09-13 伊莱利利公司 聚乙二醇连接的glp－1化合物
WO2006074600A1 (fr) * 2005-01-14 2006-07-20 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Exendines modifiees et utilisations correspondantes
CN101868476A (zh) * 2007-09-05 2010-10-20 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途

Also Published As

Publication number Publication date
CN102786590A (zh) 2012-11-21
WO2012155780A1 (zh) 2012-11-22
CN103492412B (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
CN103492412A (zh) 分枝型peg修饰的glp-1类似物及其可药用盐
CN100540565C (zh) 修饰的Exendins及其应用
RU2498814C2 (ru) Пэг-модифицированный эксендин или аналог эксендина и его композиции и применение
CN111253475B (zh) Glp-1激动多肽化合物及其盐与合成方法及用途
US8716221B2 (en) Modified exendins and uses thereof
CN102532301B (zh) 一类新型的Exendin-4类似物及其制备方法
CN101213209A (zh) 新颖化合物及它们对进食行为的影响
CN105307672A (zh) 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
CN102321170B (zh) 利拉鲁肽变构体及其缀合物
CN104788556A (zh) 人胰岛素类似物及其酰化衍生物
BR112013024706B1 (pt) Método para preparar análogos de exendina peguilada e análogo de exendina peguilada
CN102532303A (zh) 聚乙二醇缀合的艾塞那肽的合成及应用
CN108676084B (zh) 艾塞那肽的修饰物及其应用
CN105985425B (zh) 一种聚乙二醇修饰的exendin类似物及其制备方法和应用
CN108822222A (zh) 一种长效化降糖减重肽，及其制备方法与应用
CN102574904A (zh) 赋予了经粘膜吸收性的胃动素样肽化合物
WO2015149627A1 (zh) 结构修饰的glp-1类似物及其制备方法
CN107698677A (zh) 胆酸‑非洲爪蟾胰高血糖素样肽‑1缀合肽及其应用
CN109721653B (zh) 一种胰高血糖素样肽-1片段类似物及其应用
CN103087174B (zh) 一种glp-1衍生物dlg3312及其固相化学合成方法
CN116589536B (zh) 一类长效glp-1/gip受体双重激动剂及其应用
CN117143221A (zh) 一种glp-1r、gipr和gcgr三重激动剂化合物
CN115819551A (zh) 一种定点改造的一类glp-1/胰高血糖素/胃泌素受体三重激动剂及其应用
TW202411244A (zh) Ｇｌｐ－１／ｇｉｐ雙激動劑及其製備方法和用途
CN117756913A (zh) 一种新型长效多肽化合物、组合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 220047 Lianyungang economic and Technological Development Zone, Jiangsu

Applicant after: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd.

Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd.

Address before: 220047 Lianyungang economic and Technological Development Zone, Jiangsu

Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd.

Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL Co.,Ltd.

COR Change of bibliographic data
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd.

Patentee after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd.

Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: Jiangsu best Pharmaceutical Co.,Ltd.

Patentee before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd.

Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: Jiangsu best Pharmaceutical Co.,Ltd.

Patentee after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd.

Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd.

Patentee before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20160323

Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd.

Address before: Lianyungang economic and Technological Development Zone, Jiangsu, China

Patentee before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd.

Patentee before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd.